3 2004 PTO/SE

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		P10/36/21 (04-04)
Application Number	10/054,611	
Filing Date	January 18, 2002	
First Named Inventor	Cech, Thomas R.	
Art Unit	1652	
Examiner Name	Malgorzata A. Walicka	
Attorney Docket Number	015389-002970US	

Fee Transmittal Form Drawing(s) Fee Attached Licensing-related Papers	After Allowance Communication to Technology Center (TC) Appeal Communication to Board of Appeals and Interferences			
	to Technology Center (TC) Appeal Communication to Board			
Amendment/Reply After Final After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/Incomplete Application Affidavits/declaration(s) Petition Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Remarks The Commissioner is author Account 20-1430.	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): Return Postcard, copies of six (6) cited references. Orized to charge any additional fees to Deposit			
SIGNATURE OF APPLICANT, ATTORNEY,	, OR AGENT			
Firm or Townsend and Townsend and Crew LLP Scott D. Ausenhus Reg. No. 42,271 Signature				
Date OBISION				
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.				
Typed or printed name Nicole M. Wartell Signature	Date 8/19/04			

I hereby certify that this correspondence is being deposited with the United

States Postal Service as first class mail in an envelope add

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TOWNSEND and TOWNSEND and CREW LLP

Attorney Docket No.: 015389-002970US

Client Reference No.: 018/182C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Cech et al.

Application No.: 10/054,611

Filed: January 18, 2002

For: METHODS FOR DETECTING NUCLEIC ACIDS ENCODING HUMAN

TELOMERASE REVERSE

TRANSCRIPTASE (AMENDED)

Examiner: Malgorzata A. Walicka

Art Unit: 1652

SUPPLEMENTAL INFORMATION **DISCLOSURE STATEMENT UNDER 37**

CFR §1.97 and §1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

Cech et al. PATENT

Application No.: 10/054,611

Page 2

representation is being made that a search has been conducted or that this statement encompasses

all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or

Notice of Allowance.

CERTIFICATION

I hereby certify that no item of information contained in the Information

Disclosure Statement filed herewith was cited in a communication from a foreign patent office in

a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item

of information contained in this Information Disclosure Statement was known to any individual

designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information

Disclosure Statement.

Applicant believes that <u>no fee is required</u> for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the

undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit

any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Scott L. Ausenhus

Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP

Two Embarcadero Center, Eighth Floor

San Francisco, California 94111-3834

Tel: 303-571-4000 Fax: 303-571-4321

SLA:nmb

60286486 v1

PTO/SB/08A (08-03)

OIPE
AUG 2 3 2004
Substitute for form 1449A/PTO RADEN

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

	Complete if Known
Application Number	10/054,611
Filing Date	January 18, 2002
First Named Inventor	Cech, Thomas R.
Art Unit	1652
Examiner Name	Malgorzata A. Walicka
Attorney Docket Number	015389-002970US

	U.S. PATENT DOCUMENTS+					
		Document Number				
Examiner Initials*	Cite No. ¹	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	A1					
	A2					

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	For	eign Patent Do	cument Kind Code ⁶ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
	B1			Tana dada (aranami,			, ignost ppos	
	B2		·					

Examiner Signature	Date Considered	

PTO/SB/08B (08-03)



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

Complete if Known		
Application Number	10/054,611	
Filing Date January 18, 2002		
First Named Inventor	Cech, Thomas R.	
Art Unit	nit 1652	
Examiner Name Malgorzata A. Walicka		
Attorney Docket Number	015389-002970US	

	NON PATENT LITERATURE DOCUMENTS				
Examiner Cite Initials * No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2		
	C1	ANDERSON, W. FRENCH "Human Gene Therapy" Nature, April 30, 1998, pp. 25-30, Vol. 392, Supp.			
	C2	CAMPBELL, KEITH & WILMUT, IAN "Totipotency or Multipotentiality of Cultured Cells: Applications and Progress" Theriogenology, January 1997, pp. 63-72, Vol. 47, Issue 1, Elsevier Science Inc.			
	СЗ	GEARHART, JOHN "New Potential for Human Embryonic Stem Cells" <i>Science</i> , November 6, 1998; pp. 1061-1062, Vol. 282, Issue 5391.			
	C4	HORNSBY, PJ et al. "Adrenocortical Cells Immortalized by Telomerase: Potential Use for <i>Ex Vivo</i> Gene Therapy" Journal of Anti-Aging Medicine, 2000, pp. 411-417, Vol. 3, No. 4.			
	C5	OSTLER ELIZABETH L. et al. "Telomerase and the Cellular Lifespan: Implications for the Aging Process" J. of Pediatric Endocrinology & Metabolism, 2000, pp. 1467-1476, Vol. 13, Supplement 6, Freund Publishing House Ltd. London.			
	C6	THOMSON, JAMES A. et al. "Embryonic Stem Cell Lines Derived from Human Blastocysts" <i>Science</i> , November 6, 1998; pp. 1145-1147, Vol. 282, Issue 5391.			
	C7				

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).
Applicant is to place a check mark here if English language Translation is attached.